(Q37236406)

19 August 2017

1 reference

title

Optimizing denileukin diftitox (Ontak) therapy (English)

1 reference

19 August 2017

Madeleine Duvic

1

1 reference

19 August 2017

Rakhshandra Talpur

series ordinal

2

1 reference

19 August 2017

language of work or name

English

0 references

publication date

1 August 2008

1 reference

19 August 2017

1 reference

19 August 2017

volume

4

1 reference

19 August 2017

issue

4

1 reference

19 August 2017

page(s)

457-469

1 reference

Denileukin diftitox as novel targeted therapy for lymphoid malignancies

19 August 2017

cites work

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.4.457

Denileukin diftitox: a biotherapeutic paradigm shift in the treatment of lymphoid-derived disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.4.457

Interleukin-2 receptor-directed therapies: antibody-or cytokine-based targeting molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.4.457

Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.4.457

Update on erythrodermic cutaneous T-cell lymphoma: report of the International Society for Cutaneous Lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.4.457

Incidence of cutaneous T-cell lymphoma in the United States, 1973-2002.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.4.457

Resistance to activation-induced cell death and bystander cytotoxicity via the Fas/Fas ligand pathway are implicated in the pathogenesis of cutaneous T cell lymphomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.4.457

Interleukin 2 binding molecule distinct from the Tac protein: analysis of its role in formation of high-affinity receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.4.457

Interleukin-2 fusion protein: an investigational therapy for interleukin-2 receptor expressing malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.4.457

Antitumor activity of DAB389IL-2 fusion toxin in mycosis fungoides

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.4.457

Prevalence and treatment of Staphylococcus aureus colonization in patients with mycosis fungoides and Sézary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.4.457

Biological correlates of acute hypersensitivity events with DAB(389)IL-2 (denileukin diftitox, ONTAK) in cutaneous T-cell lymphoma: decreased frequency and severity with steroid premedication

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.4.457

A phase-1 trial of bexarotene and denileukin diftitox in patients with relapsed or refractory cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.4.457

Vision loss following denileukin diftitox treatment: a case report of possible posterior ischemic optic neuropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.4.457

CD25 expression is correlated with histological grade and response to denileukin diftitox in cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.4.457

The AIDS resistance of naturally SIV-infected sooty mangabeys is independent of cellular immunity to the virus

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.4.457

WHO-EORTC classification for cutaneous lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.4.457

Lymphomatoid papulosis from childhood with anaplastic large-cell lymphoma of the small bowel

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.4.457

Phase II clinical studies of denileukin diftitox diphtheria toxin fusion protein in patients with previously treated chronic lymphocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.4.457

Phase II study of denileukin diftitox for relapsed/refractory B-Cell non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.4.457

Safety and efficacy of denileukin diftitox in patients with steroid-refractory acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.4.457

Denileukin diftitox for the treatment of steroid-resistant acute graft-versus-host disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.4.457

Regulatory T cells in ovarian cancer: biology and therapeutic potential

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.4.457

IL-2 immunotoxin denileukin diftitox reduces regulatory T cells and enhances vaccine-mediated T-cell immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.4.457

Administration of DAB389IL-2 to patients with recalcitrant psoriasis: a double-blind, phase II multicenter trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.4.457

21 January 2018

Identifiers

DOI

10.2217/14796694.4.4.457

1 reference

19 August 2017

1 reference